[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-563317-105":3,"detail-sidebar-cat-1-en-105":89,"doc-detail-563317-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":82,"head_meta":84,"extra_data":86,"updated_unix":88},105,"en","city-drug-tirzepatide-injectable-patient-dosing-and-counseling-guide","City Drug - Tirzepatide Injectable - Patient Dosing and Counseling Guide","","This guide provides essential clinical protocols and patient counseling directives for compounded injectable Tirzepatide. It outlines the specific medication concentration of 10 mg/ml, storage requirements, and systematic titration schedules starting at 0.25 ml per week. The document emphasizes professional management of side effects such as nausea and constipation, while clearly defining contraindications, including histories of medullary thyroid carcinoma and pancreatitis. It serves as a comprehensive reference for healthcare providers to ensure patient safety and medication efficacy during the administration of the compounded product. Furthermore, the guide highlights critical safety warnings regarding vial disposal, renal impairment, and specific patient monitoring requirements, ensuring that providers at City Drug can maintain high standards of pharmacy care for those undergoing Tirzepatide therapy.",{"@graph":14,"@context":81},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/city-drug-tirzepatide-injectable-patient-dosing-and-counseling-guide/563317/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/city-drug-tirzepatide-injectable-patient-dosing-and-counseling-guide/563317.png","ImageObject",442,249,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-10-12",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73,77],{"name":60,"@type":61,"acceptedAnswer":62},"How should the compounded Tirzepatide be stored after initial use?","Question",{"text":63,"@type":64},"The medication must be kept refrigerated and remains stable for 28 days following the first puncture of the vial.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the initial recommended dose for a patient starting Tirzepatide?",{"text":68,"@type":64},"The recommended starting dose is 0.25 ml (2.5 mg) administered subcutaneously once every week for the first four weeks, with subsequent adjustments based on patient tolerance.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the primary side effects providers should counsel patients on?",{"text":72,"@type":64},"Providers should counsel patients regarding nausea and constipation, recommending strategies such as the use of ondansetron for nausea and increasing fiber and water intake for constipation.",{"name":74,"@type":61,"acceptedAnswer":75},"What specific medical histories act as contraindications for this medication?",{"text":76,"@type":64},"Contraindications include pregnancy, nursing, history of pancreatitis, and a personal or family history of medullary thyroid carcinoma (MTC).",{"name":78,"@type":61,"acceptedAnswer":79},"What is the protocol for disposing of the medication vial?",{"text":80,"@type":64},"The FDA recommends that the vial be disposed of exactly 28 days after the first puncture.","https://schema.org",{"og:url":32,"og:type":83,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":85,"canonical":32},"index,follow",{"doc_id":87,"site_id":7},563317,1792121640,{"code":4,"msg":90,"data":91},"success",[92,97,102,107,112,117,122,127,132],{"id":93,"doc_module":22,"doc_module_name":25,"category_name":94,"show_sort_weight":95,"slug":96},11,"Presentations",90,"presentations",{"id":98,"doc_module":22,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},12,"Resumes",80,"resumes",{"id":103,"doc_module":22,"doc_module_name":25,"category_name":104,"show_sort_weight":105,"slug":106},14,"Invoices",70,"invoices",{"id":108,"doc_module":22,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},15,"Posters",60,"posters",{"id":113,"doc_module":22,"doc_module_name":25,"category_name":114,"show_sort_weight":115,"slug":116},16,"Social Media",50,"social-media",{"id":118,"doc_module":22,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},17,"Forms",40,"forms",{"id":123,"doc_module":22,"doc_module_name":25,"category_name":124,"show_sort_weight":125,"slug":126},18,"Letters",30,"letters",{"id":128,"doc_module":22,"doc_module_name":25,"category_name":129,"show_sort_weight":130,"slug":131},21,"Paper Templates",5,"papers-templates",{"id":133,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":134},158,"general-158",{"code":4,"msg":90,"data":136},{"doc_id":87,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":22,"category_id":133,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":22,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":4},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Compounded Injectable Tirzepatide Patient Dosing and Counseling Guide for Providers  \nHow supplied: The medication will arrive in a 2ml multidose vial. It will also come supplied with syringesand alcohol wipes. This medication should stay refrigerated and is stable for 28 days after first use.  \nCompound: Contains 10 mg/ml (20mg total per vial) Tirzepatide.  \nDosing: Recommended dosing as follows (patient specific titrations expected):  \n● Start with 0.25 ml (2.5 mg) subcutaneously every week for the first 4 weeks. Then increase to 0.5 ml (5 mg) subcutaneously every week thereafter. Some patients may not need or tolerate doses exceeding 0.5mls weekly, but dosing can be increased as tolerated/needed. Given this is patient specific, we expect a variety of dosing regimens.  \nCounseling:  \n● Expect to counsel on dosing as above.  \n● Common side effects:  \no Nausea – occurs particularly at initiation and at increase in dose. The nausea can be quite severe. Recommend the ondansetron ODT that is often co-prescribed. Counsel on proper ondansetron administration (30 min prior to dose increase and ever 4-6 hours after as needed)  \no Constipation – very common on this drug. Counsel to increase fiber and water intake. Also consider an OTC stool softener, digestive enzymes, or a high-quality probiotic if symptoms persist.  \n● Contraindications:  \no Allergy to any component of the compounded formulation  \no Pregnancy and nursing mothers  \no History of pancreatitis  \no History or family history of medullary thyroid carcinoma (MTC)  \no Any other contraindication to semaglutide  \no Suicidal ideation or history of suicidality  \n● Cautions:  \no Renal impairment  \no Diabetic retinopathy  \no Female patient of reproductive potential  \n● FDA recommends disposing of vial 28 days after first puncture.  \nCity Drug, 131 10th St, Evanston (307) 789-4000","cbCaiuw4Nc0jM4my","https://ap.wps.com/l/cbCaiuw4Nc0jM4my","pdf",180961,"English","# Compounded Injectable Tirzepatide Guide\n## Medication Supply and Storage\n## Dosing and Titration Protocol\n## Patient Counseling and Side Effects Management\n## Contraindications and Cautions\n## Safety and Disposal Guidelines","[{\"question\":\"How should the compounded Tirzepatide be stored after initial use?\",\"answer\":\"The medication must be kept refrigerated and remains stable for 28 days following the first puncture of the vial.\"},{\"question\":\"What is the initial recommended dose for a patient starting Tirzepatide?\",\"answer\":\"The recommended starting dose is 0.25 ml (2.5 mg) administered subcutaneously once every week for the first four weeks, with subsequent adjustments based on patient tolerance.\"},{\"question\":\"What are the primary side effects providers should counsel patients on?\",\"answer\":\"Providers should counsel patients regarding nausea and constipation, recommending strategies such as the use of ondansetron for nausea and increasing fiber and water intake for constipation.\"},{\"question\":\"What specific medical histories act as contraindications for this medication?\",\"answer\":\"Contraindications include pregnancy, nursing, history of pancreatitis, and a personal or family history of medullary thyroid carcinoma (MTC).\"},{\"question\":\"What is the protocol for disposing of the medication vial?\",\"answer\":\"The FDA recommends that the vial be disposed of exactly 28 days after the first puncture.\"}]","City Drug - Tirzepatide Injectable - Patient Dosing and Counseling Guide | PDF",1791828910]